{"id":4394,"date":"2026-11-18T06:45:00","date_gmt":"2026-11-18T10:45:00","guid":{"rendered":"https:\/\/www.insilens.com\/?p=4394"},"modified":"2026-11-18T21:45:34","modified_gmt":"2026-11-19T01:45:34","slug":"pfizer-licenses-three-starna-in-vivo-car-t-programs","status":"publish","type":"post","link":"https:\/\/www.insilens.com\/?p=4394","title":{"rendered":"Pfizer Licenses Three Starna In Vivo CAR T Programs"},"content":{"rendered":"<p><img fetchpriority=\"high\" decoding=\"async\" width=\"768\" height=\"432\" src=\"https:\/\/www.insilens.com\/wp-content\/uploads\/2026\/11\/20261118_Pfizer_Starna_Deal_and_Financing-768x432.png\" alt=\"\" class=\"attachment-medium_large size-medium_large wp-image-4409\" srcset=\"https:\/\/www.insilens.com\/wp-content\/uploads\/2026\/11\/20261118_Pfizer_Starna_Deal_and_Financing-768x432.png 768w, https:\/\/www.insilens.com\/wp-content\/uploads\/2026\/11\/20261118_Pfizer_Starna_Deal_and_Financing-300x169.png 300w, https:\/\/www.insilens.com\/wp-content\/uploads\/2026\/11\/20261118_Pfizer_Starna_Deal_and_Financing-1024x576.png 1024w, https:\/\/www.insilens.com\/wp-content\/uploads\/2026\/11\/20261118_Pfizer_Starna_Deal_and_Financing-1536x864.png 1536w, https:\/\/www.insilens.com\/wp-content\/uploads\/2026\/11\/20261118_Pfizer_Starna_Deal_and_Financing.png 1672w\" sizes=\"(max-width: 768px) 100vw, 768px\" \/><\/p>\n<p><strong>Company<\/strong><\/p>\n<p>Pfizer; Starna Therapeutics<\/p>\n<p><strong>Event Type<\/strong><\/p>\n<p>Exclusive license ($330 million upfront; up to $2.3 billion milestones)<\/p>\n<p><strong>Modality<\/strong><\/p>\n<p>In vivo CAR T via targeted LNP-delivered RNA<\/p>\n<p><strong>Asset<\/strong><\/p>\n<p>Three pre-IND autoimmune programs; platform rights<\/p>\n<p><strong>Target<\/strong><\/p>\n<p>Undisclosed<\/p>\n<p><strong>Disease Area<\/strong><\/p>\n<p>Autoimmune disease; inflammation, immunology and oncology platform rights<\/p>\n<h4>Summary<\/h4>\n<p>Pfizer signed an exclusive license for three pre-IND autoimmune in vivo CAR-T programs from Shanghai-based Starna Therapeutics. Pfizer will pay $330 million upfront; Starna can receive up to $2.3 billion in contingent development and commercial milestones plus royalties. Initial territory excludes Greater China, with an option to expand there.<\/p>\n<p>Pfizer disclosed the agreement at 6:45 a.m. Eastern November 18. It also obtained rights to use Starna\u2019s platform in inflammation, immunology and oncology, options on compounds from a separate research collaboration, and control of development and commercialization outside Greater China. Pfizer plans to make initial clinical finished product in US facilities. The headline $2.63 billion is upfront plus maximum milestones, not guaranteed consideration.<\/p>\n<h4>Deep Analysis<\/h4>\n<p><strong>Interpretation A:<\/strong> a large cash commitment and Pfizer\u2019s RNA manufacturing capabilities could accelerate targeted lipid-nanoparticle delivery of CAR-encoding RNA to immune cells, bypassing ex vivo collection and expansion.<\/p>\n<p><strong>Interpretation B:<\/strong> Pfizer is buying breadth and geographic optionality before human proof; the three assets are pre-IND, with no disclosed target, indication, dose, biodistribution, CAR expression duration or comparative efficacy. Autoimmune immune-reset claims require durable disease control without sustained B-cell aplasia or excessive infection. Cell-selective delivery, liver uptake, innate RNA sensing, cytokine release, repeat dosing, off-target transfection, batch consistency and cross-border rights remain central gates. The Chinese origin does not itself establish global portability; US IND-quality CMC and multicenter population evidence are needed.<\/p>\n<h4>Company and Product Background<\/h4>\n<p>Starna develops RNA medicines and targeted LNP delivery. The licensed pre-IND programs aim to express CAR constructs in patient immune cells in vivo for autoimmune disease; precise targets and diseases were not disclosed. Pfizer holds initial development rights outside Greater China.<\/p>\n<h4>Signal Extraction<\/h4>\n<ul>\n<li>Primary Pfizer release verifies structure and terms; platform performance remains company assertion.<\/li>\n<li>Missing: asset codes, target antigens, LNP targeting ligand, preclinical dose-response, Starna human data and milestone schedule.<\/li>\n<li>Upgrade: independent biodistribution and first-human selective CAR expression with acceptable safety.<\/li>\n<li>Downgrade: broad off-target uptake or transient expression unable to sustain clinical response.<\/li>\n<\/ul>\n<h4>InSilens Take<\/h4>\n<p>The license validates strategic appetite for in vivo immune-cell engineering and Chinese delivery platforms, not treatment readiness or competitive displacement of established ex vivo CAR-T.<\/p>\n<h4>Signal Assessment<\/h4>\n<p>Signal Importance: 5 of 5. Signal Direction: neutral. Confidence in Facts: High. Confidence in Interpretation: Moderate.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Pfizer signed an exclusive license for three pre-IND autoimmune in vivo CAR-T programs from Shanghai-based Starna Therapeutics. Pfizer will pay $330 million upfront; Starna can receive up to $2.3 billion in contingent development and&#8230;<\/p>\n","protected":false},"author":1,"featured_media":4409,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[2],"tags":[1440,122,1535],"class_list":["post-4394","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-deals-and-financing","tag-in-vivo-car-t-2","tag-pfizer","tag-starna-therapeutics"],"blocksy_meta":[],"_links":{"self":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/4394","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=4394"}],"version-history":[{"count":1,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/4394\/revisions"}],"predecessor-version":[{"id":4420,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/4394\/revisions\/4420"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/media\/4409"}],"wp:attachment":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=4394"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=4394"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=4394"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}